Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in moderate to severe atopic dermatitis (HILLIER)
NCT04605094Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Benralizumab with Placebo / Benralizumab (2 arms). Primary endpoint: Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of >=2 Points at 16 weeks. Started Nov 2020; status: terminated.
02
Drugs
benralizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04605094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605094.